Evidence map›Paper›PMID 39333410›Full record

SynthesisAbdominal radiology (New York)2025

Is concurrent LR-5 associated with a higher rate of hepatocellular carcinoma in LR-3 or LR-4 observations? An individual participant data meta-analysis.

Nicole Abedrabbo, Emily Lerner, Eric Lam, Diana Kadi, Haben Dawit, Christian van der Pol, Jean-Paul Salameh, Haresh Naringrekar, Robert Adamo, Mostafa Alabousi and 34 more

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Abdominal radiology (New York), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Current State of Evidence for Use of MRI in LI-RADS.Journal of magnetic resonance imaging : JMRI · 2025
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

44 authors.

Nicole Abedrabbo *Duke University School of Medicine, Durham, NC, USA.
Emily Lerner *Duke University School of Medicine, Durham, NC, USA.
Eric LamThe Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Diana KadiDuke University School of Medicine, Durham, NC, USA.
Haben DawitUniversity of Toronto, Toronto, Canada.
Christian van der PolJuravinski Hospital and Cancer Centre, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada.
Jean-Paul SalamehThe Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Haresh NaringrekarThomas Jefferson University, Philadelphia, USA.
Robert AdamoUniversity of Ottawa, Ottawa, Canada.
Mostafa AlabousiMcMaster University, Hamilton, Canada.
Brooke LevisJewish General Hospital, Montreal, Canada.
An TangUniversity of Montreal, Montreal, Canada.
Ayman AlhasanTaibah University, Medina, Saudi Arabia.
Ashwini ArvindThe University of Texas Southwestern Medical Center, Dallas, USA.
Amit SingalDivision of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Brian AllenDuke University School of Medicine, Durham, NC, USA.
Krzysztof BartnikMedical University of Warsaw, Warsaw, Poland.
Joanna PodgórskaMedical University of Warsaw, Warsaw, Poland.
Alessandro FurlanUniversity of Pittsburgh, Pittsburgh, USA.
Roberto CannellaSection of Radiology - Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy.
Marco Dioguardi BurgioUniversité Paris Cité, Paris, France.
Milena CernyUniversity of Montreal, Montreal, Canada.
Sang Hyun ChoiUniversity of Ulsan, Ulsan, Republic of Korea.
Christopher ClarkeNottingham University Hospitals NHS Trust, Nottingham, UK.
Xiang JingTianjin Third Central Hospital, Tianjin, China.
Andrea KieransWeill Cornell Medical Center, New York, NY, USA.
Maxime RonotUniversité Paris Cité, Paris, France.
Grzegorz RosiakMedical University of Warsaw, Warsaw, Poland.
Hanyu JiangWest China Hospital of Sichuan University, Chengdu, China.
Ji Soo SongJeonbuk National University Medical School and Hospital, Jeonju, Republic of Korea.
Caecilia C ReinerUniversity Hospital of Zurich, Zurich, Switzerland.
Ijin JooSeoul National University Hospital, Seoul, Republic of Korea.
Heejin KwonDong-A University Hospital, Busan, Republic of Korea.
Wentao WangZhongshan Hospital, Fudan University, Shanghai, China.
Sheng-Xiang RaoZhongshan Hospital, Fudan University, Shanghai, China.
Federico Diaz TelliImages and Diagnosis Department, Universidad Austral, Buenos Aires, Argentina.
Federico PiñeroHepatology and Liver Transplant Unit, Universidad Austral, Buenos Aires, Argentina.
Nieun SeoYonsei University Health System, Seoul, Republic of Korea.
Hyo-Jin KangSeoul National University Hospital, Seoul, Republic of Korea.
Jin WangSun Yat-sen University, Guangzhou, China.
Ji Hye MinDepartment of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Andreu CostaQueen Elizabeth II Health Sciences Centre, Halifax, Canada.
Matthew McInnesThe Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Mustafa BashirDuke University School of Medicine, Durham, NC, USA. mustafa.bashir@duke.edu.

Funding

Clinical Validation Center for Hepatocellular CarcinomaU01CA271887 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI FASIHA KANWAL, JORGE A MARRERO · 2022 to 2026
$4.7M
Precision Risk Stratification and Screening for HCC among Patients with Indeterminate Liver NodulesU01CA283935 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HOSHIDA, YUJIN, SINGAL, AMIT · 2023 to 2025
$3.9M
NCI NIH HHS U01 CA283935NIH HHS U01 CA271887the European Union - FESR or FSE, PON Research and Innovation DM 1062/2021
6 · The paper itself

Abstract

backgroundThe Liver Imaging Reporting and Data System (LI-RADS) does not consider factors extrinsic to the observation of interest, such as concurrent LR-5 observations. PURPOSE: To evaluate whether the presence of a concurrent LR-5 observation is associated with a difference in the probability that LR-3 or LR-4 observations represent hepatocellular carcinoma (HCC) through an individual participant data (IPD) meta-analysis.

methodsMultiple databases were searched from 1/2014 to 2/2023 for studies evaluating the diagnostic accuracy of CT/MRI for HCC using LI-RADS v2014/2017/2018. The search strategy, study selection, and data collection process can be found at https://osf.io/rpg8x . Using a generalized linear mixed model (GLMM), IPD were pooled across studies and modeled simultaneously with a one-stage meta-analysis approach to estimate positive predictive value (PPV) of LR-3 and LR-4 observations without and with concurrent LR-5 for the diagnosis of HCC. Risk of bias was assessed using a composite reference standard and Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2).

resultsTwenty-nine studies comprising 2591 observations in 1456 patients (mean age 59 years, 1083 [74%] male) were included. 587/1960 (29.9%) LR-3 observations in 1009 patients had concurrent LR-5. The PPV for LR-3 observations with concurrent LR-5 was not significantly different from the PPV without LR-5 (45.4% vs 37.1%, p = 0.63). 264/631 (41.8%) LR-4 observations in 447 patients had concurrent LR-5. The PPV for LR-4 observations with concurrent LR-5 was not significantly different from LR-4 observations without concurrent LR-5 (88.6% vs 69.5%, p = 0.08). A sensitivity analysis for low-risk of bias studies (n = 9) did not differ from the primary analysis.

conclusionThe presence of concurrent LR-5 was not significantly associated with differences in PPV for HCC in LR-3 or LR-4 observations, supporting the current LI-RADS paradigm, wherein the presence of synchronous LR-5 may not alter the categorization of LR-3 and LR-4 observations.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMagnetic Resonance ImagingTomography, X-Ray ComputedHumansPredictive Value of TestsConcurrentHepatocellular carcinomaLI-RADSLR-3LR-4Positive predictive value

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.